API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide, in patients with metastatic prostate cancer progressing on enzalutamide.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: ORIC-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
ORIC-101 is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 plasma concentrations provided excellent target coverage.
Lead Product(s): ORIC-101,Paclitaxel
Therapeutic Area: Oncology Product Name: ORIC-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The data demonstrate that GR may be a mechanism of resistance to AR degraders and that in vitro, ORIC-101 overcomes GR-driven resistance to AR degradation.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: ORC-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
ORIC-101 overcame GR-mediated resistance to chemotherapeutic agents including taxanes, antimetabolites and platinums, in both in vitro and in vivo efficacy studies spanning a variety of solid tumor types.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: ORC-101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The IPO proceeds will push ORIC Pharma's lead program through phase 1b and into phase 2 and move its second program into the clinic.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 23, 2020
Details:
The funding is directed towards company's advancing pipeline of drug candidates for the treatment of prostate cancer and solid tumors.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 20, 2020
Details:
Study based on preclinical evidence suggesting ORIC-101, may inhibit a potential mechanism of resistance to XTANDI® in patients with metastatic prostate cancer.
Lead Product(s): ORIC-101,Enzalutamide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2020